Quanterix Co. (NASDAQ:QTRX) Director David R. Walt Acquires 131,869 Shares

Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director David R. Walt bought 131,869 shares of Quanterix stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $5.43 per share, with a total value of $716,048.67. Following the completion of the purchase, the director now directly owns 1,628,802 shares of the company's stock, valued at approximately $8,844,394.86. The trade was a 8.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Quanterix Price Performance

Shares of NASDAQ:QTRX traded down $0.31 during mid-day trading on Monday, reaching $5.06. 793,619 shares of the company traded hands, compared to its average volume of 580,059. The company's 50 day moving average price is $5.28 and its 200-day moving average price is $7.87. Quanterix Co. has a 52 week low of $4.05 and a 52 week high of $19.18. The firm has a market cap of $196.47 million, a PE ratio of -4.77 and a beta of 1.05.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The business had revenue of $30.33 million during the quarter, compared to analyst estimates of $28.27 million. On average, research analysts predict that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QTRX has been the topic of several recent analyst reports. Leerink Partnrs downgraded shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 price target (down from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Canaccord Genuity Group lowered their price objective on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Quanterix has a consensus rating of "Hold" and a consensus target price of $15.60.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its position in Quanterix by 1.8% in the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock valued at $1,150,000 after acquiring an additional 1,963 shares in the last quarter. Jane Street Group LLC grew its holdings in Quanterix by 4.2% in the first quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock valued at $380,000 after purchasing an additional 2,366 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Quanterix by 219.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after buying an additional 3,915 shares in the last quarter. Hsbc Holdings PLC boosted its stake in Quanterix by 25.8% in the 4th quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock worth $205,000 after buying an additional 3,974 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after purchasing an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 86.48% of the company's stock.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.